Introduction
============

Although \>80% of the pancreas is composed of acinar cells and only 4% of the organ is composed of ductal epithelial cells, acinar cell carcinoma (ACC) represents \<1% of all pancreatic neoplasms and is much rarer than pancreatic ductal adenocarcinoma (DAC).[@b1-ott-9-5475]--[@b5-ott-9-5475] DAC is an aggressive malignancy with a very poor prognosis. This tumor is the major histological subtype and comprises 90% of all pancreatic cancers.[@b6-ott-9-5475],[@b7-ott-9-5475] ACC is not well defined pathologically due to its rarity. There are only a few reports on the imaging performance, treatment, and outcome of ACC, and most of them are only case reports or small number series.[@b4-ott-9-5475],[@b5-ott-9-5475],[@b8-ott-9-5475]--[@b10-ott-9-5475] Many issues concerning this tumor remain unclear.[@b11-ott-9-5475] In particular, there is no consensus regarding the preoperative distinction of ACC from other pancreatic neoplasms. ACCs were previously considered to be as aggressive as DACs and pretreatment differentiation between tumor types was not considered important.[@b12-ott-9-5475],[@b13-ott-9-5475] However, recently, several studies have reported that the malignant potential and treatment principles for ACC are very different from DAC. In previous reports, 76.5% of the ACCs in patients were considered resectable, and the 5-year survival rate after resection is 43.9%.[@b14-ott-9-5475],[@b15-ott-9-5475] Even if ACC is unresectable or recurrent, chemotherapy, such as paclitaxel and 5-fluorouracil, is often still effective.[@b13-ott-9-5475],[@b16-ott-9-5475] Thus, a radiological differential diagnosis before beginning treatment is important to achieve better prognosis.

In this study, we retrospectively examined patients with ACC confirmed pathologically in the past 7 years in Zhongshan Hospital. The features of ACC were evaluated and compared with DAC by computed tomography (CT) scans to improve our understanding of ACC diagnosis and treatment.

Materials and methods
=====================

Patients
--------

This study was approved by the Institutional Ethics Committee of Zhongshan Hospital, and informed consent was not required because the review of the patient data was all anonymous.

CT technique
------------

All patients received plain and enhanced CT scans preoperatively using American GE Light Speed (Fairfield, CT, USA) or German Siemens SOMATOM Definition (Munich, Germany). The main parameters included the following: 1.5--2.5 mm detector collimation, 12.5--27 mm table speed per gantry rotation, 3--5 mm section thickness, and 3--5 mm reconstruction interval. A routine abdominal dynamic CT consisting of unenhanced, arterial, and portal venous phase imaging was performed. The arterial and port venous phases were obtained 20--40 and 60--80 seconds after starting intravenous injection of the contrast material. The patients were administered 1.5 mL/kg iohexol (Omnipaque 370; Amersham, Shanghai, People's Republic of China) with a mechanical injector at a rate of 3 mL/s.

Image interpretation
--------------------

All the images acquired by CT were reviewed by two radiologists with 6 and 11 years diagnostic imaging experience, respectively. The radiologists were blinded to the clinical findings and pathological results. The images were reviewed using a picture archiving and communication system (EBM Medical Information system, Shanghai, People's Republic of China). The CT images from each patient were reviewed to analyze the imaging criteria. The tumor location was classified as head--neck and body--tail. The dividing line was the superior mesenteric artery. The diameter was defined by the mean of the long- and short-axis diameter at the level of maximum tumor diameter. The tumor texture was classified as homogeneous or heterogeneous (with intratumoral necrosis). The pancreatic duct and common bile duct dilation were defined as \>3 and 10 mm, respectively. The CT attenuation value in Hounsfield units (HUs) was obtained using a region of interest (ROI) analysis. The ROI cursors were carefully placed to encompass as much of the tumor as possible and avoid necrotic areas and adjacent structures. The ROI value was calculated as the CT attenuation value of the tumor. Three ROIs 1 cm in diameter were also identified in the normal parenchyma adjacent to the tumor. The mean of the three ROI values was calculated as the CT attenuation value of the normal pancreas. When defining ROI, we excluded all cystic areas, calcification, the pancreatic duct, and the surrounding vessels.

Pathological examination
------------------------

A pathological examination of all tumors was performed on specimens obtained during surgery. All tumors were surgically resected after CT scan. Hematoxylin and eosin--stained sections and immunohistochemical analysis of the tumor specimens were reviewed by two pathologists to ensure the diagnosis.

Statistical analysis
--------------------

In this study, the ratios of CT attenuation values were used to indicate the distinction between tumor and pancreas parenchyma. We denoted the CT values of tumor and pancreas in unenhanced, arterial, and port venous phases as *T*~0~, *T*~a~, *T*~p~, and *P*~0~, *P*~a~, *P*~p~, respectively. The ratios of *T*~0~/*P*~0~, *T*~a~/*P*~a~, *T*~p~/*P*~p~, (*T*~a~ − *T*~0~)/(*P*~a~ − *P*~0~), and (*T*~p~ − *T*~0~)/(*P*~p~ − *P*~0~) were calculated and their log transformations between ACCs and DACs were examined by independent-sample *t*-tests. The differences in the tumor CT attenuation values obtained by the unenhanced and contrast-enhanced CT imaging were compared by the paired-samples *t*-test. The differences in size and CT attenuation between ACCs and DACs were also compared using the independent-samples *t*-test. The comparison of qualitative data was determined using the chi-square test. A two-side *P*-value \<0.05 was considered a statistically significant difference. All data collection and statistical analysis were performed using the SPSS software (version 15.0, SPSS Inc., Chicago, IL, USA).

Results
=======

Patient selection
-----------------

The pathology database of our hospital was searched from January 2008 to December 2015 by using the terms "pancreatic cancer" or "pancreatic tumor" ([Figure 1](#f1-ott-9-5475){ref-type="fig"}). There were 624 records reviewed after the database search and 283 cases were excluded. A total of 98 patients were excluded because the CT scanning results before surgical pancreatectomy were not recorded in our hospital. Given that an increased number of controls could not improve the validity of test when the ratio of the case to control was beyond 1:4,[@b17-ott-9-5475] a sampling process that randomly selected one in four cases was used to generate a subset of DAC patients as the control group for ACC patients. In this study, we collected 14 cases with ACC and 34 cases with DAC for the comparison analysis ([Figure 1](#f1-ott-9-5475){ref-type="fig"}).

ACCs characteristics
--------------------

The clinical data for the 14 ACC cases are listed in [Table 1](#t1-ott-9-5475){ref-type="table"}. The age of the patients ranged from 28 to 78 years (mean 58.1±13.7 years). The female (n=2, 14.3%) to male (n=12, 85.7%) ratio was 1:6. The majority of patients (n=11, 78.6%) had symptoms of abdominal pain and underwent a CT scan in the out-patient department. There were two tumors (14.3%) in the pancreas found during a routine physical examination. One tumor was found by the CT scan of a patient with jaundice.

All the ACC tumors were located in the pancreas and the tumor sizes ranged from 16 to 78 mm (mean 50.1±24.2 mm). Six of 14 tumors (42.9%) were located in the pancreas head--neck and eight (57.1%) were located in the body--tail ([Figure 2](#f2-ott-9-5475){ref-type="fig"}). The tumor texture was homogeneous in nine of 14 cases (64.3%) and there were five (35.7%) cases with intratumoral necrosis ([Figure 3](#f3-ott-9-5475){ref-type="fig"}). CT imaging also demonstrated a variety of features, including a large tumor involving artery and spleen ([Figure 4](#f4-ott-9-5475){ref-type="fig"}). There was common bile duct dilation in two (2/14, 14.3%) patients and one patient (1/14, 7.1%) with pancreatic ductal obstructions.

The mean attenuation of ACC was 35.4±3.9 HU before enhancement, 73.1±42.9 HU in arterial phase, and 71.8±15.6 HU in port venous phase ([Figure 5](#f5-ott-9-5475){ref-type="fig"}). A significant difference was detected in attenuation of tumors before and after administration of contrast media (*P*\<0.05). However, the paired-sample *t*-test demonstrated there were no significant differences of CT attenuation for ACC and normal pancreatic parenchyma in unenhanced, arterial, and port venous phases (*P*\>0.05).

Comparison with DAC
-------------------

We compared the ACC and DAC patient characteristics by statistical analyses. The patient age and sex were not different between groups ([Table 2](#t2-ott-9-5475){ref-type="table"}). The chi-square test demonstrated there was no difference in the tumor location. However, the size of ACC tumors was significantly larger than DAC tumors (50.1±24.2 vs 21.7±6.2 mm). The occurrence rate of necrosis in ACC patients was significantly higher than that in DAC cases (5/14 vs 2/34). Fisher's exact probability test indicated that biliary dilation (ACC vs DAC =2/14 vs 16/34) and pancreatic ductal dilation (ACC vs DAC =1/14 vs 29/34) in ACC was significantly less than DAC (*P*\<0.05). An independent-samples *t*-test showed there were no differences of CT attenuation values for the two groups with respect to measured values, variation, and logarithmic transformation of ratios ([Table 2](#t2-ott-9-5475){ref-type="table"}).

Discussion
==========

The pathogenesis of ACC is largely unknown due to the infrequent diagnosis. However, it is accepted that the molecular mechanisms involved are different from those of the more frequent DACs and neuroendocrine tumors.[@b1-ott-9-5475],[@b18-ott-9-5475] ACCs present as a distinct microsatellite stable and chromosomal unstable genotype with mutations in DCC and c-Myc with loss of APC gene function. Clinically, the postoperative survival and resection rates of ACC were reported to be superior to DAC in a multi-institutional study (median survival, 61 vs 24 months).[@b12-ott-9-5475] There is no consensus on the treatment of ACCs. However, surgery greatly improves the prognosis.[@b19-ott-9-5475] In addition, several reports have described a good prognosis after intervention with therapeutic regimens, such as FOLFIRINOX and S1, which differ from the treatments used in DAC patients.[@b8-ott-9-5475],[@b9-ott-9-5475] The malignant potential of ACC is significantly different from DAC. With proper regional, systemic, and targeted therapy, advanced ACC patients can survive \>7 years after diagnosis.[@b10-ott-9-5475] Thus, correct pretreatment distinction between these ACCs and DACs is very important.[@b20-ott-9-5475] If we can clearly distinguish ACCs and DACs, perhaps we can select a more suitable pretreatment for both types of patients.

ACCs originate from the pancreatic acinar cells rather than the ductal epithelium.[@b21-ott-9-5475] Clinically, ACC patients commonly show symptoms related to a local mass or metastases, which rarely cause dilatation of the pancreatic duct. Therefore, patients with ACC typically present with abdominal pain as opposed to painless obstructive jaundice. The presentation with jaundice is more typical of DAC of the pancreatic head. Consistent with these findings, most patients in our series had abdominal pain without jaundice ([Table 1](#t1-ott-9-5475){ref-type="table"}). Other patient subgroups with ACC presented with an interesting unique syndrome called "lipase hypersecretion syndrome,"[@b2-ott-9-5475] which is characterized by skin rashes, polyarthralgias, fevers, and fat necrosis because of lipase secretion by the tumor into the blood. Though we did not find an age difference in the current study, a previous large population study showed that ACC patients tend to occur at a younger age than DAC (56 vs 70 years, *P*\<0.001).[@b22-ott-9-5475] But, we do not think younger patients will get a longer overall survival between the two kinds of different tumors because the survival is determined by many factors, such as malignant degree, complications, and comorbidities. Schmidt et al[@b11-ott-9-5475] reported that patients were more likely to have ACC than DAC if they were male, white, had larger tumors, or a lesion in the tail of the pancreas. In our study, both sex and tumor location in patients with ACC were not statistically different from patients with DAC ([Table 2](#t2-ott-9-5475){ref-type="table"}). This result may be due to the small case number bias and the ratio of sex which is as high as 1:6 (female:male). Our findings showed the size of ACC tumors was larger than DAC tumors. This result is consistent with a previous study.[@b23-ott-9-5475]

Recent reports using CT have shown that ACCs are typically solitary and are homogenously enhanced when the lesion is small. The tumor may show hypodensity due to necrosis if the lesion is large.[@b23-ott-9-5475]--[@b25-ott-9-5475] One possible explanation for the necrotic portion is the digestive effect of the pancreatic enzymes released by neoplastic cells. A previous report described ACCs as a hyperdense tumor in the arterial phase after administration of contrast media.[@b4-ott-9-5475] Other studies reported ACC tended to be enhanced less than the adjacent normal pancreatic parenchyma.[@b2-ott-9-5475],[@b3-ott-9-5475] In our study, most cases (11/14) were hypodense in unenhanced, arterial, and port venous phases ([Figure 2](#f2-ott-9-5475){ref-type="fig"}). However, the CT attenuation values were not statistically different between tumors and normal pancreatic parenchyma in unenhanced, arterial, and port venous phases. So, from our study and reported cases, it seems that not every ACC shows a unique attenuation pattern.

We examined the pattern of CT attenuation values before and after administering contrast media to compare the ACC results with DAC, which is the most frequently suspected disease in the preoperative diagnosis. Sumiyoshi et al[@b20-ott-9-5475] reported that the time attenuation curve of ACC had a peak enhancement during arterial or port venous phase but not in delayed phase in a dynamic CT scanning. The results were different in DAC patients. However, we found the measured values and variations could not distinguish the two diseases. We also attempted to use novel indicators calculated with the CT attenuation values. These indicators included the ratio of attenuation value of tumors relative to normal pancreas for assessing if there were variation changes between abnormal and normal pancreas in CT imaging. Unfortunately, these indicators were not significantly different between ACC and DAC.

Limitations
===========

There are limitations present in our study. First, the case number is small due to the rarity of ACCs. Second, the study only enrolled patients who were pathologically identified after surgical pancreatectomy. Thus, the patterns do not represent late-stage patients with ACC or patients with metastatic tumors. Third, as a retrospective study, the CT imaging parameters were not consistent and delayed CT imaging was absent.

Conclusion
==========

The patterns of CT attenuation were similar for ACC in multiple phases with enhanced CT scanning. In addition, recently documented intraductal and papillary variants of ACCs are even more challenging for the differential diagnosis with DAC.[@b26-ott-9-5475] Thus, CT imaging alone is not sufficient to differentiate ACC from DAC preoperatively. However, from our study, we found that ACC is more likely to be larger and contains more heterogeneous, intratumoral necrotic, and hypovascular regions on CT imaging. In addition, the presence of pancreatic ductal dilation and biliary dilation may be helpful to distinguish ACCs from DACs but it is not certain. Future studies about this aspect are needed. Novel CT imaging modalities in combination with magnetic resonance imaging,[@b21-ott-9-5475] 18-fluorodeoxyglucose positron emission tomography,[@b27-ott-9-5475] and serum biomarkers, such as elevated serum alpha fetoprotein,[@b4-ott-9-5475] should be explored to improve the differential diagnosis for ACC and DAC.
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![Study flowchart.\
**Abbreviation:** CT, computed tomography.](ott-9-5475Fig1){#f1-ott-9-5475}

![Acinar cell carcinoma from the body of the pancreas in a 52-year-old male (**A**--**C**), and from the tail in a 49-year-old male (**D**, **E**).\
**Notes:** (**A**, **D**) Axial enhanced computed tomography (CT) in arterial phase demonstrated the tumors (arrows) were relatively hypovascular compared with normal pancreas parenchyma, and pancreatic ductal dilation was not found. (**B**, **E**) In port venous phase after administering contrast media, the CT attenuation of tumors (arrows) were close to pancreas tissue. (**C**, **F**) Coronal CT reformation showed the location of tumors (arrows).](ott-9-5475Fig2){#f2-ott-9-5475}

![Acinar cell carcinoma in a 78-year-old male.\
**Notes:** (**A**) Axial computed tomography (CT) imaging before enhancement showed a heterogeneous tumor in the head of the pancreas (arrow). (**B**) Areas of hypoattenuation due to necrosis (arrow) were found in the axial CT imaging in arterial phase after enhancement. (**C**) A coronal view of tumor in port venous phase showed the common bile duct was not obstructed (arrow).](ott-9-5475Fig3){#f3-ott-9-5475}

![Acinar cell carcinoma in a 58-year-old male.\
**Notes:** (**A**) Axial computed tomography (CT) imaging before enhancement by contrast media showed a large poorly defined mass with hypoattenuation in the tail of the pancreas. (**B**) The splenic artery was included in the mass in arterial phase after administering contrast media (arrow head). (**C**) Axial enhanced CT in port venous phase showed the infiltrative mass involving the spleen (arrow).](ott-9-5475Fig4){#f4-ott-9-5475}

![Mean attenuation of acinar cell carcinoma (ACC) patients.\
**Notes:** *T*~0~, *T*~a~, *T*~p~ attenuation value for tumor in unenhanced, arterial, and port venous phases, respectively; *P*~0~, *P*~a~, *P*~p~ attenuation value for pancreatic parenchyma in unenhanced, arterial, and port venous phases, respectively.\
**Abbreviation:** HU, Hounsfield unit.](ott-9-5475Fig5){#f5-ott-9-5475}

###### 

Data of patients with ACC

  Patient   Age (years)   Sex   Symptoms   Size (mm)   Location   Necrosis   Biliary obstruction   Pancreatic obstruction
  --------- ------------- ----- ---------- ----------- ---------- ---------- --------------------- ------------------------
  1         61            F     AP         78.25       HNU        N          Y                     N
  2         57            M     AP         16.2        BT         Y          N                     N
  3         76            M     N          17.6        HNU        N          N                     N
  4         35            M     AP         72.0        BT         N          N                     N
  5         78            M     AP         37.1        HNU        Y          N                     N
  6         52            M     AP         21.4        BT         N          N                     N
  7         58            M     AP         48.0        BT         Y          N                     N
  8         28            M     AP         21.5        HNU        N          N                     N
  9         49            M     AP         67.5        BT         Y          N                     N
  10        65            M     N          67.5        HNU        Y          N                     N
  11        53            M     AP         50.8        BT         N          N                     Y
  12        68            F     AP         69.6        BT         N          N                     N
  13        71            M     N          63.5        HNU        N          Y                     N
  14        62            M     AP         46          BT         N          N                     N

**Abbreviations:** AP, abdominal pain; ACC, acinar cell carcinoma; BT, body--tail; F, female; HNU, head--neck--uncinate; M, male; N, none; Y, yes.

###### 

Characteristic comparison between ACC and DAC patients

  Items                                   ACC              DAC              *P*-value   Statistic methods
  --------------------------------------- ---------------- ---------------- ----------- ---------------------------------
  Age                                     58.1±13.7        60.8±9.9         \>0.05      Independent-samples *t*-test
  Sex (F:M)                               2:12             13:21            \>0.05      Chi-square test with correction
  Location (HNU:BT)                       6:8              23:11            \>0.05      Chi-square test with correction
  Necrosis (P:N)                          5:9              2:32             \<0.05      Chi-square test with correction
  Biliary dilation (P:N)                  2:12             16:18            \<0.05      Chi-square test with correction
  Pancreatic ductal dilation (P:N)        1:13             29:5             \<0.05      Fisher's exact probability test
  Size (mm)                               50.1±24.2        21.7±6.2         \<0.05      Independent-samples *t*-test
  *T*~0~ (HU)                             35.4±3.9         32.6±3.6         \>0.05      Independent-samples *t*-test
  *T*~a~ (HU)                             73.1±42.9        58.9±15.5        \>0.05      Independent-samples *t*-test
  *T*~p~ (HU)                             71.8±15.6        72.1±15.8        \>0.05      Independent-samples *t*-test
  Log (*T*~0~/*P*~0~)                     *−*0.022±0.064   *−*0.064±0.070   \>0.05      Independent-samples *t*-test
  Log (*T*~a~/*P*~a~)                     *−*0.181±0.159   *−*0.187±0.106   \>0.05      Independent-samples *t*-test
  Log (*T*~p~/*P*~p~)                     *−*0.076±0.102   0.096±0.134      \>0.05      Independent-samples *t*-test
  *T*~a~*−T*~0~ (HU)                      37.7±42.1        26.3±16.1        \>0.05      Independent-samples *t*-test
  *T*~p~*−T*~0~ (HU)                      36.3±14.5        39.5±15.1        \>0.05      Independent-samples *t*-test
  Log ((*T*~a~*−T*~0~)/(*P*~a~*−P*~0~))   *−*0.730±0.731   *−*0.785±0.593   \>0.05      Independent-samples *t*-test
  Log ((*T*~p~*−T*~0~)/(*P*~p~*−P*~0~))   *−*0.296±0.443   0.286±0.618      \>0.05      Independent-samples *t*-test

**Notes:** *P*~0~, *P*~a~, *P*~p~ attenuation value for pancreatic parenchyma in unenhanced, arterial, port venous phase, respectively; *T*~0~, *T*~a~, *T*~p~ attenuation value for tumor in unenhanced, arterial, port venous phase, respectively.

**Abbreviations:** ACC, acinar cell carcinoma; BT, body--tail; DAC, ductal adenocarcinoma; F, female; HNU, head--neck--uncinate; HU, Hounsfield unit; M, male; N, negative; P, positive.
